TissueCypher® is the first diagnostic test of its kind that predicts the risk of developing esophageal cancer in patients with Barrett’s Esophagus.
Video - Cernostics TissueCypher® Technology & DDW 2016
Barrett's Esophagus & Esophageal Cancer
Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn howNews
View All News
08/31/2016
UPMC Partners with Cernostics to Pursue ‘Precision Medicine’... Read More
05/11/2016
Cernostics Announces Scientific Presentations at DDW and ISPOR Meetings Demonstrating Clinical Validation and Cost-Effectiveness of New TissueCypher® Barrett's Esophagus Assay... Read More
10/29/2015
Ground-breaking Cancer Diagnostic Technology Receives Phase 2 SBIR Grant... Read More
Events
10/18/2014 — Vienna, Austria
UEG Week (United European Gastroenterology Week)
06/23/2014 — San Diego, CA
BIO International Convention
05/03/2014 — Chicago, IL
DDW (Digestive Disease Week)
01/13/2014 — San Francisco, CA
JP Morgan Healthcare Conference
11/13/2013 — Philadelphia, PA
PA BIO Life Sciences Future Meeting
